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Abstract. In order to investigate the involvement of the IER3/
PP2A-B56γ/ERK-positive feedback loop, which leads to 
sustained phosphorylation/activation of ERK in carcinogen-
esis, we immunohistochemically examined the expression of 
IER3 and phosphorylated ERK in lung tumor tissues. IER3 
was overexpressed in all cases of adenocarcinomas examined, 
but was not overexpressed in squamous cell carcinomas. 
Phosphorylated ERK (pERK) was also overexpressed in almost 
all adenocarcinomas. EGFR and RAS, whose gene product is 
located upstream of ERK, were sequenced. Activating muta-
tion of EGFR, which is a possible cause of overexpression of 
IER3 and pERK, was found only in 5 adenocarcinomas (42%). 
No mutation of RAS was found. We further examined the 
sequences of all exons of B56γ gene (PPP2R5C) and IER3, 
but no mutation was found. Using a single nucleotide insertion 
in intron 1 of PPP2R5C, which was found in the process of 
sequencing, allelic deletion of PPP2R5C was examined. Eight 
cases were informative (67%), and the deletion was found in 
4 of them (50%). Three cases having deletion of PPP2R5C did 
not have EGFR mutation. Finally, PPP2R5C deletion or EGFR 
mutation that could be responsible for IER3/pERK overex-
pression was found in at least 8 cases (67% or more). This is 
the first report of a high incidence of deletion of PPP2R5C in 
human carcinomas.
Introduction
IER3 (immediate early response gene 3) was first identified 
in fibroblasts from mouse in 1993 (1), and human IER3, 
formerly referred to as the immediate early gene X-1 (IEX-1), 
was first identified in human squamous cell carcinomas. The 
human IER3 gene is located on the short arm of chromo-
some 6 (6p21.3) and has 2 exons. The gene encodes 156 amino 
acids (2). IER3 protein is rapidly and transiently induced by 
a variety of stimuli, including ionizing radiation, inflamma-
tory cytokines, viral infection, anti-cancer drugs and growth 
factors (2,3), and is associated with apoptosis and cell prolif-
eration (3,4). As it is involved in cell growth, IER3 expression 
has been examined in several human tumors, including 
pancreatic carcinoma, ovarian carcinoma, breast cancer, and 
myelodysplastic syndrome (5-8). However, there has been no 
study of IER3 expression in human lung carcinoma.
Protein phosphatase 2A (PP2A), which consists of struc-
tural subunit A, regulatory subunits B, and catalytic subunit C, 
has a broad spectrum of functions due to the variety of regula-
tory subunits, of which there are more than 20 kinds (9). PP2A 
can act as a tumor suppressor (10,11). B56 regulatory subunits 
are involved in cell proliferation signaling (11,12). Among 
them, PP2A-B56γ1 dephosphorylates Thr202 of phosphorylated 
extracellular signal-regulated kinase (pERK), leading to inac-
tivation of ERK (13). Furthermore, Garcia et al (14) found that 
the regulation of cell growth by IER3 is mediated by ERK, 
which also plays a central role in regulation of a variety of 
cellular events, including cell proliferation, differentiation, 
migration, and apoptosis (15,16). IER3 regulates ERK activity 
through its inhibitory activity on B56-containing PP2A, which 
dephosphorylates ERK (13). Recently it has been clarified that 
activated ERK induces IER3 protein synthesis, and then IER3 
inhibits B56γ1-PP2A, forming the ERK/IER3/B56γ1-PP2A 
positive feedback loop, which eventually leads to sustained 
activation of ERK (17). The duration of ERK activation is 
considered to be one of the factors that determine cellular 
events (18,19). Thus, IER3 and PP2A should contribute to 
multiple cellular processes, including tumorigenesis, via regu-
lation of ERK.
In this context, mutation of the B56γ gene (PPP2R5C), 
which is located at 14q32.31, in lung carcinomas as well as 
other carcinomas has been reported (20). Deletion of 14q 
has also been reported in lung carcinoma (21). PPP2R5C is 
frequently involved in loss of heterozygosity (LOH) in 14q32 
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in a variety of carcinomas (22,23), which suggests an impor-
tant role of B56γ in carcinogenesis. Furthermore, BL6 mouse 
melanoma cells, in which B56γ is truncated, are highly meta-
static (24). In a patient with Sezary syndrome, translocation 
of t(14;14) (q11;q32) caused rearrangement of PPP2R5C (25). 
All of these findings indicate an important role of B56γ in 
carcinogenesis. We recently showed that the ERK/IER3/
B56γ1 loop is activated by the growth factor-induced RAS/
RAF/mEK/ERK cascade (17). After growth factor binds to 
epidermal growth factor receptor (EGFR), RAS, RAF, mEK 
and ERK are activated sequentially by phosphorylation or 
binding (26). The cascade is frequently constitutively activated 
by mutation or gene amplification in lung adenocarcinomas, 
including mutation of EGFR, amplification of HER2, muta-
tion of RAS, and mutation of RAF. Among these changes, 
mutations of EGFR and RAS are most frequent. Activating 
EGFR mutations are found in 5-30% (as high as 50-60% in 
Asian populations) of non-small cell lung carcinomas, while 
K-RAS mutations are found in 20-12%, and RAF mutations in 
<1% (27,28). Furthermore, it was reported that phosphoryla-
tion of ERK was closely associated with mutation of RAS or 
EGFR (29).
The aim of this study was to examine whether the IER3/
B56γ1-PP2A/ERK-positive feedback loop is involved in carci-
nogenesis of non-small cell lung carcinoma. We also report the 
high prevalence in these carcinomas of allelic deletion of B56γ 
gene, which is a major cause of secondary overexpression of 
IER3/pERK.
Materials and methods
Tumor samples. Tumor samples, including normal tissues, 
were obtained from 16 lung cancer patients (12 adenocarci-
nomas and 4 squamous cell carcinomas) who were operated 
at Kanazawa University Hospital from September 2013 to 
December 2014. Tissue specimens were frozen at -80˚C.
This work was approved by the ethics committee of 
Kanazawa University. We obtained informed consent from all 
patients, and all studies were performed on the basis of the 
declaration of Helsinki and the ethical guidelines for human 
genome and gene analysis of the ministry of Health, Labour 
and Welfare, Japan.
Immunohistochemistry. Sections (5 µm) were cut from 
formalin-fixed, paraffin-embedded (FFPE) tissues. To unmask 
epitopes, the sections were treated with Target Retrieval 
Solution (pH 9.0, Dako, Uppsala, Sweden). Endogenous 
peroxidase activity was blocked with 3% H2O2. Sections 
were reacted with specific rabbit antibodies against human 
IER3 antibody (Abnova, Taipei, Taiwan) at 1:500 dilution, 
or specific antibodies against Thr202/Tyr204-phosphorylated 
p42/44 ERK (Cell Signaling Technology, Danvers, mA, USA) 
at 1:100 dilution, and then reacted with peroxidase-labeled 
dextran goat anti-rabbit IgG (Dako). Diaminobenzidine 4HCl 
(Histofine SAB-PO (M) kit, Nichirei, Tokyo, Japan) was used 
for visualization. Negative controls were done on serial tissue 
sections using 0.5% BSA or with antigen-absorbed antibody.
Glutathione-S-transferase (GST) fusion IER3 protein, 
which was used to absorb antibodies against IER3, was puri-
fied with GST beads. Fusion IER3 protein (1 mg) was added 
to 20 µl of antibody solution, and rocked for 60 min at room 
temperature. Then, the reaction mixture was centrifuged 
at 14,000 rpm for 10 min. To evaluate possible differences 
of positivity between non-tumor epithelia and carcinoma 
cells, the ratio of positive cells were counted in 5 randomly 
selected areas.
Laser capture microdissection. Frozen sections of lung tumor 
tissues were fixed with 100% ethanol for 2 min and stained 
with 0.1% toluidine blue (merck, Darmstadt, Germany). 
Approximately 1,000 carcinoma cell sections were cut out 
using a Laser microdissection system (LmD 7000, Leica 
microsystems, Inc., Bensheim, Germany), and collected in 
a 0.5 ml RNase-free PCR tube. Extraction of genomic DNA 
was performed from the frozen sections using a ReliaPrep™ 
gDNA Tissue miniprep System (Promega, madison, WI, 
USA). Extraction of RNA was performed using an SV Total 
Isolation system (Promega), and reverse transcription to cDNA 
was performed using an RT-PCR system.
Direct sequencing. Extraction of genomic DNA from frozen 
sections was performed using a ReliaPrep gDNA Tissue 
Miniprep System (Promega). Specific primer sets were used 
for amplification of human EGFR, K-RAS, PPP2R5C (B56γ1 
gene) and IER3. Exons 18, 19, 20 and 21 in EGFR and exon 2 
in K-RAS, which are hot spots of mutation (30), were evaluated 
(Table I). All of the exons of PPP2R5C (13 exons) and IER3 
(2 exons) were amplified and sequenced. PCR amplification 
was performed with KOD Fx Neo (Toyobo Co., Ltd., Tokyo, 
Japan). Cycle sequencing reaction was performed using a 
Big Dye Terminator v1.1 Cycle Sequencing kit (Applied 
Biosystems, Foster City, USA). The sequencing reactions were 
conducted with a capillary sequencer (ABI PRISm 3130x1 
Genetic Analyzer, Applied Biosystems).
TA cloning. Fresh PCR products amplified using taq DNA 
polymerase (Takara Ex Taq®, Takara, Kusatsu, Japan) were 
ligated into linearized pCRTm 2.1-TOPO® vectors in a TOPO 
TA cloning kit (Invitrogen, Carlsbad, CA, USA) using T4 DNA 
ligase. The ligated vectors were transformed into competent 
TOP10 cells and grown overnight on LB agar plates containing 
ampicillin and X-gal. Blue-white screening was performed for 
inserts. The ligated clones were purified and the inserts were 
sequenced using the m13 (-20) forward primer and a Big Dye 
Terminator v1.1 Cycle Sequencing kit.
Analysis of LOH in PPP2R5C. A single nucleotide insertion 
in intron 1 in PPP2R5C, found in the present study, was used 
for analyzing LOH. The 3' portions of intron 1 and exon 2 
were amplified with the primer sets used to sequence exon 2 
(Table I). When the single nucleotide insertion/deletion was 
found in one allele and not found in the other allele (i.e., dupli-
cated peaks were seen in the electropherogram of the normal 
lung tissue), the status was considered informative. When the 
duplicated peaks were not found in the electropherogram of 
the corresponding tumor, the status was considered LOH.
Statistics. One-way analysis of variance was used for comparing 
the numbers of immunohistochemically positive carcinoma 
cells, normal bronchiolar epithelia or alveolar epithelia. When 
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a significant difference was found, multivariate analysis using 
Dunnett's multiple comparison test was applied.
Results
Immunohistochemical detection of IER3. A few bronchiolar 
epithelial cells were positive to anti-IER3 antibodies (Fig. 1A). 
IER3 was immunolocalized in the nuclei. In adenocarcinoma, 
IER3 was strongly immunostained in nuclei and faintly in 
cytoplasm (Fig. 1B). Granular staining remained positive 
in cytoplasm when antigen-absorbed antibody was used, 
suggesting that it was non-specific. Therefore, we considered 
that only the nuclear staining was positive in the present study. 
All the adenocarcinomas showed large numbers of positive 
cells, whereas squamous cell carcinomas showed far fewer 
positive cells (Fig. 1C).
We counted positive cells in 5 fields of a high-power 
microscope and calculated the ratio of IER3-positive cells 
Figure 1. Expression of IER3 evaluated by immunohistochemistry. (A) Respiratory bronchiole. Arrows indicate IER3-positive cells. (B) Adenocarcinoma 
(case 5). (C) Squamous cell carcinoma (case 15).
Figure 2. Positive ratio of IER3 determined by immunohistochemistry. (A) Comparisons among bronchiolar epithelia (Bronchiole), adenocarcinomas (AC) and 
squamous cell carcinomas (SCC). (B) Comparisons between bronchiolar epithelia and each case of carcinoma. The asterisks indicate a statistically significant 
difference between bronchiolar epithelia and carcinomas (*p<0.01).
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in each field. The ratios were significantly higher in adeno-
carcinomas (p<0.01) than in alveolar or bronchiolar epithelia. 
The average ratio of IER3-positive cells in adenocarcinomas 
was 4-8 times higher than that in normal epithelia. The ratio in 
squamous cell carcinomas was not significantly different from 
that in bronchiolar epithelia (Fig. 2A). ANOVA followed by 
Dunnett's multiple comparison showed that the ratios in all the 
adenocarcinomas were significantly higher (p<0.01) than that 
in normal epithelia (Fig. 2B). None of the squamous cell carci-
nomas showed a significant difference from normal epithelia.
Table I. The primer sets for direct sequencing.
Genes 1st pair of PCR primers Nested primers
EGFR  GCTCTGTAGAGAAGGCGAC GCTCTGTAGAGAAGGCGTAC
Exon 18  TCCCAAACACTCAGTGAAACAAA TTGGTCTCACAGGACCACTG
EGFR  CCCCAGCAATATCAGCCTTA GTGCATCGCTGGTAACATCC
Exon 19  GTGGATACCAGCATGGGAGA TGTGGAGATGAGCAGGGTCT
EGFR  TGAAACTCAAGATCGCATTCA ATCGCATTCATGCGTCTTCA
Exon 20  TGGGACAGGCACTGATTTGT ATCCCCATGGCAAACTCTTG
EGFR  AGCCATAAGTCCTCGACGTG GCTCAGAGCCTGGCATGAA
Exon 21  TGGCTCACACTACCAGGAGA CATCCTCCCCTGCATGTGT
KRAS  ACGTCTGCAGTCAACTGGAA GGAGTATTTGATAGTGTATTAACCT
Exon 2  ACCCACTGTATGAGGGTTCC AGAATGGTCCTGCACC
IER3  CATAAATTACCTCTGCCGGC CTCACTTGGCCTTACACTCC
Exon 1  TCAAGTTGCCTCGGAAGTCC AAACAGGAGACAGGTCAGGT
IER3  CATAAATTACCTCTGCCGGC ACCTGACCTGTCTCCTGTTT
Exon 2 TCAAGTTGCCTCGGAAGTCC CGCCTGGTGTTTCTTTGTGG
PPP2R5C  TGCTGACATCACGAACCAGC TTCCCGCTGAAGTCTAG
Exon 1  CACCCAACCTCCTCTGGTTA CCGATTCAGTGAACACAC
PPP2R5C  CTAACAGTGCTCTCAACATGG ATATGACCAGCGACTAGCTG
Exon 2  TAGGCTCAGAGATCTTGGCC AAATCAGAACTGGGACAC
PPP2R5C  TACGGAGGAGCTAAGTTACC GCGGCTACTGTTAGAATTACC
Exon 3  ACATCTTCACTGGCTGTTG CATGCTACTGAGGAGGAGAG
PPP2R5C  TGTAGTCTGTGGGTTTCACC GTGGCTTTGAGAGGCTAATA
Exon 4-5 TCCTGTCAGAGGAGACGATG AATGAGCATCACCACACAC
PPP2R5C  AGATGCGCTTCTTGTTGCCTG ATGGCTCCTCCTAGAGCATTG
Exon 6 TCTAAGAGCTCACCAACTCC CAGCTGGACTCAATGAAATG
PPP2R5C  ACAGGTGCATGGCAACATGC GCTGGGTTTTGATGGTGA
Exon 7 AGGCCGGATTCACTATCTCG CTGTGTTCCTAGAGTCCTG
PPP2R5C  GTTAATGCCCGTTAATCACAC GGGAAGGTGTTTAACGATG
Exon 8 CCATGAATGAAATGAGCCTG GCAATTTGGTGAAGCAGATG
PPP2R5C CACAGACTTCTTACCATGCAG CATCAGTCACTCCACGTGTC
Exon 9 TGCATGAGAGGCAAAGCATG GCTACGCATGGAACTTTTCC
PPP2R5C GGTTACAGGTTACAGTCTAG TCTGGTCCAAGGTAGTTCAT
Exon 10 GAGTCCACAAAGCAACTGAC ATGGCAGCCAGTTCTTTC
PPP2R5C  CAAGTAACGCGGAATGAGCAG ACTGTTGGAATATGGAGCAG
Exon 11 GCTTTCGAGTGAAGAATACCG GTGGAAGAGGTTTACTTAGG
PPP2R5C  CTCAACATGCCTGTGCCTT TGTGTTCTTGTGTCTGATGC
Exon 12 CACAGTCTCAGGCTGTATTC ACGTTAGTGAAATCGAGACC
PPP2R5C  TGTTGCAGGTGTAGGCGAGT ATGAGAAGCTTGGAGTTCAG
Exon 13 CAGCTTAAACAGAAGGCACTG TGCAAATCACATCGCCTAC
PPP2R5C TGGATGCGGCCAACTCCAAT AACTCCAATGGGCCTTTCC
Exon 1-2 GAGGAAGGTGGTAATGTTCG ACGTTGGTTCATCTTCCTCC
PPP2R5C CGCAACACTGACGTAACTTC CAGATGTTCCTCCTGCTGAT
Intron 1  ATATGACCAGCGACTAGCTG GGAATAGCCTTTGTTTACCC
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Immunohistochemical detection of phosphorylated ERK. 
Phosphorylated ERK was immunostained in both nuclei and 
cytoplasm of bronchiolar epithelia (Fig. 3A). In the present 
study, only cells immunostained in the nuclei were considered 
positive. The pattern of distribution of pERK-positive cells was 
different from that of IER3-positive cells. pERK-positive cells 
were restricted to the peripheral areas of the tumor in adeno-
carcinomas, and negative areas were excluded from evaluation 
of the cell count. pERK was intensely stained mainly in the 
nuclei (Fig. 3B). Positive cells were stained in small clusters, 
which were distributed evenly throughout squamous cell 
carcinoma (Fig. 3C).
The ratio of pERK expression was significantly higher in 
almost all adenocarcinomas than in normal epithelia, except 
for 1 case. None of the squamous cell carcinomas showed a 
significant difference from normal epithelia (Fig. 4A). When 
Figure 3. Expression of phosphorylated ERK (pERK) evaluated by immunohistochemistry. (A) Respiratory bronchiolar epithelia. Arrows indicate pERK-
positive cells. (B) Adenocarcinoma (case 4). (C) Squamous cell carcinoma (case 15).
Figure 4. Positive ratio of pERK determined by immunohistochemistry. (A) Comparisons among bronchiolar epithelia (Bronchiole), adenocarcinomas (AC) 
and squamous cell carcinomas (SCC). (B) Comparisons between bronchiolar epithelia and each case of carcinoma. The asterisks indicate a statistically 
significant difference between bronchiolar epithelia and carcinomas (p<0.01).
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the ratios in all the cases were compared, multiple comparison 
showed a significant difference in adenocarcinoma, but not in 
squamous cell carcinoma (Fig. 4B).
Direct sequencing. To examine the relationship between IER3/
pERK overexpression in adenocarcinoma and alteration of the 
EGFR-ERK cascade or the ERK/IER3/B56γ1 feedback loop, 
we looked for mutations in the sequences of EGFR, K-RAS, 
PPP2R5C and IER3. The results are summarized in Table II.
In 12 cases of adenocarcinoma, EGFR mutation was found 
in 5 cases; deletion of EGFR exon 19 (746-750del) was found 
in 2 cases. In the other 3 cases, point mutation was found in 
EGFR exon 21 (L861Q or L858R). No mutation of K-RAS 
exon 2 was found. No EGFR and K-RAS mutations were found 
in squamous cell carcinomas. IER3 showed no mutation in any 
of the cases.
In the process of sequencing of PPP2R5C, we observed 
intermittent duplicated waves in the electropherograms from 
samples of non-tumor lung tissues, indicating the presence 
of a mixture of different sequences. Insertion or deletion 
of one nucleotide in the first intron in one allele apparently 
generated the duplication. We further designed a primer 
set spanning intron 1, and confirmed the duplication by TA 
cloning analysis. The sequence of one allele is the same as 
the reported sequence (accession no., NC 000014), while 
the sequence of the other allele showed insertion of a single 
nucleotide (G) 122 bases upstream of the end of the first intron 
(IVS1-122insG). The electropherogram using cDNA and the 
primer sets (Table I) amplifying the boundary of exon 1 and 
exon 2 showed single waves of the reported sequence (acces-
sion no. Nm 002719). Finally, it was concluded that there was 
no mutation in PPP2R5C in any of the cases.
Analysis of LOH at PPP2R5C using the single nucleotide 
insertion. Heterozygous sequences in intron 1 of PPP2R5C 
were found in 8 out of 12 cases (67%) in the non-tumor tissue 
and in 4 out of 12 cases (33%) in the tumor. Finally, 4 out of 8 
informative cases were heterozygous, and 4 were homozygous 
(50%), indicating LOH (Fig. 5).
Discussion
IER3 inhibits PP2A-B56γ, resulting in inhibition of ERK 
dephosphorylation (13,17), so that overexpression of IER3 could 
result in sustained activation of ERK, leading to cell prolifera-
tion. Our immunohistochemical findings that both IER3 and 
Table II. Protein overexpression, gene mutations and allelic deletion of PPP2R5C.
 Overexpression mutation Deletion -------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------
Case IER3 pERK EGFR KRAS IER3 PPP2R5C PPP2R5C
1 + - -  -  -  -  -
2 + + L858R  -  -  -  -
3 + + -  -  -  -  Not informative
4 + + L858R  -  -  -  -
5 + + L861Q  -  -  -  -
6 + + 746-753del  -  -  -  Not informative
7 + + 746-750del  -  -  -  +
8 + + -  -  -  -  Not informative
9 + + -  -  -  -  +
10 + + -  -  -  -  +
11 + - -  -  -  -  Not informative
12 + + -  -  -  -  +
Figure 5. Electropherograms around the heterozygous point of the single nucleotide (G) insertion at -122 in intron 1 of the PP2A-B56γ gene. T, tumor; NT, 
non-tumor.
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pERK were overexpressed in adenocarcinomas support this 
idea. However, it was not clear whether the overexpression was 
due directly to changes of IER3 or ERK, or to an alteration of 
upstream signaling protein, such as EGFR. EGFR exons 18, 
19, 20 and 21 encode an intracellular tyrosine kinase, and 
mutations in these regions cause ligand-independent EGFR 
activation (31), leading to overexpression of pERK through 
the EGFR/RAS/RAF/mEK cascade (26,32). We found EGFR 
mutation in 42% of lung adenocarcinomas, and all of the 
EGFR mutation cases showed pERK overexpression. This is 
consistent with the results of a previous study (33). In addition, 
overexpression of ERK by IHC is reported to be positive in 
89% of lung adenocarcinomas that overexpress EGFR (34). 
Thus, it is strongly suggested that overexpression of pERK/
IER3 is caused by activating mutation of EGFR. However, in 
the cases with no mutation of EGFR, there is no obvious reason 
for pERK/IER3 overexpression. Therefore, we considered 
the possible role of a positive feedback loop of ERK/IER3/
PP2A-B56γ1 in the nucleus (17). Both IER3 and pERK were 
overexpressed in the nucleus in adenocarcinomas examined 
by us, which is consistent with the existence of an ERK/IER3/
PP2A-B56γ1-positive feedback loop in lung adenocarcinoma. 
This positive feedback loop may be involved in carcinogenesis 
of lung adenocarcinoma (35).
Recently, Garcia et al (36) proposed that pERK enhanced 
the immediate expression of IER3 in pancreatic cancer, and 
they found that IER3 is prominently expressed in pancreatic 
ductal adenocarcinoma. IER3 expression sustains phosphory-
lation of ERK through PP2A. Invasive breast cancer (7) and 
multiple myeloma (37) show high IER3 expression, but on 
the contrary, IER3 expression in ovarian cancer is lower than 
in benign cystadenomas (6). This might reflect the fact that 
IER3 has apparently contradictory functions of proapoptosis 
and cell proliferation (3,4), possibly by inhibiting the activities 
of other B56 species involved in different signaling pathways 
from B56γ (13). The positive correlation of IER3 expression 
and pERK expression may suggest that the interaction of 
IER3/ERK promotes cell proliferation.
PP2A-B56γ1 dephosphorylates and inactivates ERK, 
and inhibits cell proliferation and migration (15,17). PP2A 
functions as a tumor-suppressor gene (38,39). One of the 
mechanisms of inactivation of tumor-suppressor genes is 
allelic deletion or loss of heterozygosity (LOH). PPP2R5C 
(PP2A B56γ gene) is located at the tip of the long arm of chro-
mosome 14 (14q32.31). Deletion of 14q has been reported in 
lung non-small cell carcinoma (21), and may be relevant to the 
present findings. The reported 14q deletion in lung non-small 
cell carcinoma occurred only in 4% of cases (21), which is 
much less frequent than 50% in the present study. However, 
much more frequent LOH at shorter portions in 14q have been 
reported (40,41), although LOH of 14q32 has not been exam-
ined for lung carcinoma. LOH of 14q32 was found in 32-44% 
of colorectal cancers (22,42), and is associated with metastatic 
recurrence (42). LOH was also found in 31% of neuroblas-
tomas (43), 37% of esophageal cancers (23), and 16% of gastric 
cancers (44). Breast carcinoma with BRCA2 mutation shows 
14q32 LOH in 80% of cases, which may suggest the presence 
of tumor suppressor genes at 14q32 (45).
Suppressor genes including RB and TP53, which are 
recessive genes, are mutated or deleted in one allele in addi-
tion to deletion in the other allele in lung carcinomas (46). In 
the present study, LOH at PPP2R5C was found frequently, 
but we did not find mutation of PPP2R5C. Therefore, some 
other mechanism of cPP2A-B56γ inactivation must exist if 
PP2A-B56γ is involved in carcinogenesis. PP2A consists of 
three subunits, A, B and C. Deletion or inactivating mutation 
in the subunit A or C gene, in addition to allelic deletion of 
B56γ, would further reduce function of PP2A-B56γ. Subunit 
A gene, PPP1R1B, is mutated in 15% of lung and colon 
cancers (47), and expression of Aβ is lost in colon cancer (48). 
The Aβ gene is located at 11q22-23, and 11q is deleted in 20% 
of lung cancers (21). Further, 11q22-24 is deleted in 63% of 
lung adenocarcinomas (49). The subunit C gene, PPP2CA, is 
located at 5q, which is deleted in 20% of lung carcinomas (21). 
Taken together, these findings suggest it is highly likely that 
PP2A-B56γ function is frequently lost in lung adenocarcinoma, 
as well as other carcinomas such as colorectal carcinoma, 
leading to overexpression of IER3/pERK. We found LOH of 
PPP2R5C in 50% of lung adenocarcinomas, and many of them 
did not appear to have any other mutation that might cause 
IER3/pERK overexpression. Thus, deletion of 14q32 could be 
an important factor in carcinogenesis of the lung.
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